{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T07:49:58Z","timestamp":1787903398760,"version":"build-2784847793"},"reference-count":106,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,8]],"date-time":"2025-06-08T00:00:00Z","timestamp":1749340800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,6,8]],"date-time":"2025-06-08T00:00:00Z","timestamp":1749340800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Harm Reduct J"],"DOI":"10.1186\/s12954-025-01242-8","type":"journal-article","created":{"date-parts":[[2025,6,8]],"date-time":"2025-06-08T09:57:00Z","timestamp":1749376620000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Evaluation of implementing drug checking services for anabolic androgenic steroids in Switzerland: a pilot study"],"prefix":"10.1186","volume":"22","author":[{"given":"Raphael","family":"Magnolini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Kaeppeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Schori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Bruggmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Senn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"\u2018DIZ\u201c Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,8]]},"reference":[{"issue":"1","key":"1242_CR1","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1186\/s12889-022-13734-4","volume":"22","author":"R Magnolini","year":"2022","unstructured":"Magnolini R, Falcato L, Cremonesi A, Schori D, Bruggmann P. Fake anabolic androgenic steroids on the black market - a systematic review and meta-analysis on qualitative and quantitative analytical results found within the literature. BMC Public Health. 2022;22(1):1371.","journal-title":"BMC Public Health"},{"key":"1242_CR2","doi-asserted-by":"publisher","first-page":"40080","DOI":"10.57187\/smw.2023.40080","volume":"153","author":"M Kruijver","year":"2023","unstructured":"Kruijver M, Bruggmann P, Magnolini R. Evidence of use and users of image- and performance-enhancing drugs in sports in Switzerland: a scoping literature review and implications for Swiss drug policy. Swiss Med Wkly. 2023;153:40080.","journal-title":"Swiss Med Wkly"},{"issue":"2","key":"1242_CR3","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1128\/JVI.79.2.1252-1261.2005","volume":"79","author":"MB Zwick","year":"2005","unstructured":"Zwick MB, Jensen R, Church S, Wang M, Stiegler G, Kunert R, et al. Anti-human immunodeficiency virus type 1 (HIV-1) antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membrane-proximal external region of glycoprotein gp41 to neutralize HIV-1. J Virol. 2005;79(2):1252\u201361.","journal-title":"J Virol"},{"issue":"10","key":"1242_CR4","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1002\/j.1875-9114.2012.01123","volume":"32","author":"EJ Ip","year":"2012","unstructured":"Ip EJ, Lu DH, Barnett MJ, Tenerowicz MJ, Vo JC, Perry PJ. Psychological and physical impact of anabolic-androgenic steroid dependence. Pharmacotherapy. 2012;32(10):910\u20139.","journal-title":"Pharmacotherapy"},{"issue":"7","key":"1242_CR5","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1007\/s11606-021-06751-3","volume":"36","author":"AK Bonnecaze","year":"2021","unstructured":"Bonnecaze AK, O\u2019Connor T, Burns CA. Harm reduction in male patients actively using anabolic androgenic steroids (AAS) and performance-enhancing drugs (PEDs): a review. J Gen Intern Med. 2021;36(7):2055\u201364.","journal-title":"J Gen Intern Med"},{"issue":"6","key":"1242_CR6","doi-asserted-by":"publisher","first-page":"155798832096653","DOI":"10.1177\/1557988320966536","volume":"14","author":"AK Bonnecaze","year":"2020","unstructured":"Bonnecaze AK, O\u2019Connor T, Aloi JA. Characteristics and attitudes of men using anabolic androgenic steroids (AAS): a survey of 2385 men. Am J Mens Health. 2020;14(6):1557988320966536.","journal-title":"Am J Mens Health"},{"key":"1242_CR7","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.mce.2017.02.039","volume":"464","author":"G Kanayama","year":"2018","unstructured":"Kanayama G, Pope HG. History and epidemiology of anabolic androgens in athletes and non-athletes. Mol Cell Endocrinol. 2018;464:4\u201313.","journal-title":"Mol Cell Endocrinol"},{"issue":"5","key":"1242_CR8","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.annepidem.2014.01.009","volume":"24","author":"D Sagoe","year":"2014","unstructured":"Sagoe D, Molde H, Andreassen CS, Torsheim T, Pallesen S. The global epidemiology of anabolic-androgenic steroid use: a meta-analysis and meta-regression analysis. Ann Epidemiol. 2014;24(5):383\u201398.","journal-title":"Ann Epidemiol"},{"key":"1242_CR9","doi-asserted-by":"publisher","first-page":"1214374","DOI":"10.3389\/fcvm.2023.1214374","volume":"10","author":"K Fadah","year":"2023","unstructured":"Fadah K, Gopi G, Lingireddy A, Blumer V, Dewald T, Mentz RJ. Anabolic androgenic steroids and cardiomyopathy: an update. Front Cardiovasc Med. 2023;10:1214374.","journal-title":"Front Cardiovasc Med"},{"key":"1242_CR10","doi-asserted-by":"publisher","first-page":"732318","DOI":"10.3389\/frph.2021.732318","volume":"3","author":"DL Smit","year":"2021","unstructured":"Smit DL, Voogel AJ, den Heijer M, de Ronde W. Anabolic androgenic steroids induce reversible left ventricular hypertrophy and cardiac dysfunction. Echocardiography results of the HAARLEM study. Front Reprod Health. 2021;3:732318.","journal-title":"Front Reprod Health."},{"issue":"5","key":"1242_CR11","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1002\/ehf2.12494","volume":"6","author":"S Doleeb","year":"2019","unstructured":"Doleeb S, Kratz A, Salter M, Thohan V. Strong muscles, weak heart: testosterone-induced cardiomyopathy. ESC Heart Fail. 2019;6(5):1000\u20134.","journal-title":"ESC Heart Fail"},{"key":"1242_CR12","doi-asserted-by":"crossref","unstructured":"Windfeld-Mathiasen J, Heerfordt IM, Dalhoff KP, Tr\u00e6rup Andersen J, Andersen MA, Johansson KS, et al. Cardiovascular disease in anabolic androgenic steroid users. circulation. 2025.","DOI":"10.1161\/CIRCULATIONAHA.124.071117"},{"issue":"26","key":"1242_CR13","doi-asserted-by":"publisher","first-page":"3071","DOI":"10.3748\/wjg.v28.i26.3071","volume":"28","author":"A Petrovic","year":"2022","unstructured":"Petrovic A, Vukadin S, Sikora R, Bojanic K, Smolic R, Plavec D, et al. Anabolic androgenic steroid-induced liver injury: an update. World J Gastroenterol. 2022;28(26):3071\u201380.","journal-title":"World J Gastroenterol"},{"issue":"1","key":"1242_CR14","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.nefroe.2019.06.005","volume":"40","author":"SLA Parente Filho","year":"2020","unstructured":"Parente Filho SLA, Gomes PEAC, Forte GA, Lima LLL, Silva J\u00fanior GBD, Meneses GC, et al. Kidney disease associated with androgenic-anabolic steroids and vitamin supplements abuse: Be aware! Nefrologia (Engl Ed). 2020;40(1):26\u201331.","journal-title":"Nefrologia (Engl Ed)"},{"issue":"8","key":"1242_CR15","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1681\/ASN.2020010028","volume":"31","author":"GJ Ko","year":"2020","unstructured":"Ko GJ, Rhee CM, Kalantar-Zadeh K, Joshi S. The effects of high-protein diets on kidney health and longevity. J Am Soc Nephrol. 2020;31(8):1667\u201379.","journal-title":"J Am Soc Nephrol"},{"key":"1242_CR16","doi-asserted-by":"crossref","unstructured":"Albano GD, Amico F, Cocimano G, Liberto A, Maglietta F, Esposito M, et al. Adverse effects of anabolic-androgenic steroids: a literature review. Healthcare (Basel). 2021;9(1).","DOI":"10.3390\/healthcare9010097"},{"issue":"2","key":"1242_CR17","first-page":"61","volume":"90","author":"A Gupta","year":"2021","unstructured":"Gupta A, Thorson P, Penmatsa KR, Gupta P. Rhabdomyolysis: revisited. Ulster Med J. 2021;90(2):61\u20139.","journal-title":"Ulster Med J"},{"issue":"6","key":"1242_CR18","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1176\/appi.ajp.2009.08111699","volume":"166","author":"G Kanayama","year":"2009","unstructured":"Kanayama G, Brower KJ, Wood RI, Hudson JI, Pope HG. Issues for DSM-V: clarifying the diagnostic criteria for anabolic-androgenic steroid dependence. Am J Psychiatry. 2009;166(6):642\u20135.","journal-title":"Am J Psychiatry"},{"issue":"12","key":"1242_CR19","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1111\/j.1360-0443.2009.02734.x","volume":"104","author":"G Kanayama","year":"2009","unstructured":"Kanayama G, Brower KJ, Wood RI, Hudson JI, Pope HG. Anabolic-androgenic steroid dependence: an emerging disorder. Addiction. 2009;104(12):1966\u201378.","journal-title":"Addiction"},{"issue":"5","key":"1242_CR20","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1016\/j.fertnstert.2014.02.002","volume":"101","author":"CD Rahnema","year":"2014","unstructured":"Rahnema CD, Lipshultz LI, Crosnoe LE, Kovac JR, Kim ED. Anabolic steroid-induced hypogonadism: diagnosis and treatment. Fertil Steril. 2014;101(5):1271\u20139.","journal-title":"Fertil Steril"},{"issue":"1","key":"1242_CR21","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s13011-023-00573-8","volume":"18","author":"B Grant","year":"2023","unstructured":"Grant B, Kean J, Vali N, Campbell J, Maden L, Bijral P, et al. The use of post-cycle therapy is associated with reduced withdrawal symptoms from anabolic-androgenic steroid use: a survey of 470 men. Subst Abuse Treat Prev Policy. 2023;18(1):66.","journal-title":"Subst Abuse Treat Prev Policy"},{"key":"1242_CR22","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1146\/annurev.me.42.020191.002313","volume":"42","author":"RH Strauss","year":"1991","unstructured":"Strauss RH, Yesalis CE. Anabolic steroids in the athlete. Annu Rev Med. 1991;42:449\u201357.","journal-title":"Annu Rev Med"},{"issue":"3","key":"1242_CR23","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s11154-015-9320-5","volume":"16","author":"E Nieschlag","year":"2015","unstructured":"Nieschlag E, Vorona E. Doping with anabolic androgenic steroids (AAS): adverse effects on non-reproductive organs and functions. Rev Endocr Metab Disord. 2015;16(3):199\u2013211.","journal-title":"Rev Endocr Metab Disord"},{"issue":"1","key":"1242_CR24","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1017\/S0950268814000727","volume":"143","author":"VD Hope","year":"2015","unstructured":"Hope VD, McVeigh J, Marongiu A, Evans-Brown M, Smith J, Kimerg\u00e5rd A, et al. Injection site infections and injuries in men who inject image- and performance-enhancing drugs: prevalence, risks factors, and healthcare seeking. Epidemiol Infect. 2015;143(1):132\u201340.","journal-title":"Epidemiol Infect"},{"issue":"9","key":"1242_CR25","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2013-003207","volume":"3","author":"VD Hope","year":"2013","unstructured":"Hope VD, McVeigh J, Marongiu A, Evans-Brown M, Smith J, Kimerg\u00e5rd A, et al. Prevalence of, and risk factors for, HIV, hepatitis B and C infections among men who inject image and performance enhancing drugs: a cross-sectional study. BMJ Open. 2013;3(9): e003207.","journal-title":"BMJ Open"},{"issue":"1","key":"1242_CR26","doi-asserted-by":"publisher","first-page":"2337717","DOI":"10.1080\/07853890.2024.2337717","volume":"56","author":"B Karagun","year":"2024","unstructured":"Karagun B, Altug S. Anabolic-androgenic steroids are linked to depression and anxiety in male bodybuilders: the hidden psychogenic side of anabolic androgenic steroids. Ann Med. 2024;56(1):2337717.","journal-title":"Ann Med"},{"issue":"3","key":"1242_CR27","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1192\/apt.bp.105.000935","volume":"13","author":"H Rashid","year":"2007","unstructured":"Rashid H, Ormerod S, Day E. Anabolic androgenic steroids: what the psychiatrist needs to know. Adv Psychiatr Treat. 2007;13(3):203\u201311. https:\/\/doi.org\/10.1192\/apt.bp.105.000935.","journal-title":"Adv Psychiatr Treat"},{"issue":"1","key":"1242_CR28","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1097\/00042752-199501000-00005","volume":"5","author":"DA Malone","year":"1995","unstructured":"Malone DA, Dimeff RJ, Lombardo JA, Sample RH. Psychiatric effects and psychoactive substance use in anabolic-androgenic steroid users. Clin J Sport Med. 1995;5(1):25\u201331.","journal-title":"Clin J Sport Med"},{"key":"1242_CR29","doi-asserted-by":"crossref","unstructured":"Windfeld-Mathiasen J, Heerfordt IM, Dalhoff KP, Andersen JT, Horwitz H. Mortality among users of anabolic steroids. JAMA. 2024.","DOI":"10.1001\/jama.2024.3180"},{"issue":"5","key":"1242_CR30","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1177\/1557988316648704","volume":"12","author":"JA McBride","year":"2018","unstructured":"McBride JA, Carson CC, Coward RM. The availability and acquisition of illicit anabolic androgenic steroids and testosterone preparations on the internet. Am J Mens Health. 2018;12(5):1352\u20137.","journal-title":"Am J Mens Health"},{"key":"1242_CR31","doi-asserted-by":"crossref","unstructured":"Mullen C, Whalley BJ, Schifano F, Baker JS. Anabolic androgenic steroid abuse in the United Kingdom: an update. Br J Pharmacol. 2020.","DOI":"10.1111\/bph.14995"},{"key":"1242_CR32","doi-asserted-by":"crossref","unstructured":"Ivers JH, Killeen N, Keenan E. Drug use, harm-reduction practices and attitudes toward the utilisation of drug safety testing services in an Irish cohort of festival-goers. Ir J Med Sci. 2021.","DOI":"10.1007\/s11845-021-02765-2"},{"issue":"3","key":"1242_CR33","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1111\/bcp.14231","volume":"86","author":"F Measham","year":"2020","unstructured":"Measham F. City checking: Piloting the UK\u2019s first community-based drug safety testing (drug checking) service in 2 city centres. Br J Clin Pharmacol. 2020;86(3):420\u20138.","journal-title":"Br J Clin Pharmacol"},{"issue":"5\u20136","key":"1242_CR34","doi-asserted-by":"publisher","first-page":"740","DOI":"10.17269\/s41997-018-0126-6","volume":"109","author":"SC Mema","year":"2018","unstructured":"Mema SC, Sage C, Xu Y, Tupper KW, Ziemianowicz D, McCrae K, et al. Drug checking at an electronic dance music festival during the public health overdose emergency in British Columbia. Can J Public Health. 2018;109(5\u20136):740\u20134.","journal-title":"Can J Public Health"},{"key":"1242_CR35","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.drugpo.2019.07.007","volume":"73","author":"H Valente","year":"2019","unstructured":"Valente H, Martins D, Carvalho H, Pires CV, Carvalho MC, Pinto M, et al. Evaluation of a drug checking service at a large scale electronic music festival in Portugal. Int J Drug Policy. 2019;73:88\u201395.","journal-title":"Int J Drug Policy"},{"issue":"2","key":"1242_CR36","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1111\/dar.12576","volume":"37","author":"MJ Barratt","year":"2018","unstructured":"Barratt MJ, Bruno R, Ezard N, Ritter A. Pill testing or drug checking in Australia: acceptability of service design features. Drug Alcohol Rev. 2018;37(2):226\u201336.","journal-title":"Drug Alcohol Rev"},{"key":"1242_CR37","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.drugpo.2018.11.001","volume":"67","author":"FC Measham","year":"2019","unstructured":"Measham FC. Drug safety testing, disposals and dealing in an English field: exploring the operational and behavioural outcomes of the UK\u2019s first onsite \u201cdrug checking\u201d service. Int J Drug Policy. 2019;67:102\u20137.","journal-title":"Int J Drug Policy"},{"issue":"6","key":"1242_CR38","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1111\/dar.13259","volume":"40","author":"S Murphy","year":"2021","unstructured":"Murphy S, Bright SJ, Dear G. Could a drug-checking service increase intention to use ecstasy at a festival? Drug Alcohol Rev. 2021;40(6):974\u20138.","journal-title":"Drug Alcohol Rev"},{"key":"1242_CR39","doi-asserted-by":"publisher","first-page":"103270","DOI":"10.1016\/j.drugpo.2021.103270","volume":"95","author":"F Measham","year":"2021","unstructured":"Measham F, Turnbull G. Intentions, actions and outcomes: A follow up survey on harm reduction practices after using an English festival drug checking service. Int J Drug Policy. 2021;95:103270.","journal-title":"Int J Drug Policy"},{"issue":"1","key":"1242_CR40","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s12954-018-0208-z","volume":"15","author":"M Sande","year":"2018","unstructured":"Sande M, \u0160abi\u0107 S. The importance of drug checking outside the context of nightlife in Slovenia. Harm Reduct J. 2018;15(1):2.","journal-title":"Harm Reduct J"},{"issue":"3","key":"1242_CR41","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1037\/pha0000452","volume":"29","author":"JJ Palamar","year":"2021","unstructured":"Palamar JJ, Fitzgerald ND, Keyes KM, Cottler LB. Drug checking at dance festivals: a review with recommendations to increase generalizability of findings. Exp Clin Psychopharmacol. 2021;29(3):229\u201335.","journal-title":"Exp Clin Psychopharmacol"},{"key":"1242_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2019.107589","volume":"205","author":"K McCrae","year":"2019","unstructured":"McCrae K, Tobias S, Tupper K, Arredondo J, Henry B, Mema S, et al. Drug checking services at music festivals and events in a Canadian setting. Drug Alcohol Depend. 2019;205: 107589.","journal-title":"Drug Alcohol Depend"},{"issue":"4","key":"1242_CR43","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1097\/YCO.0000000000000607","volume":"33","author":"JJ Palamar","year":"2020","unstructured":"Palamar JJ, Salomone A, Barratt MJ. Drug checking to detect fentanyl and new psychoactive substances. Curr Opin Psychiatry. 2020;33(4):301\u20135.","journal-title":"Curr Opin Psychiatry"},{"issue":"1","key":"1242_CR44","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s12954-018-0252-8","volume":"15","author":"M Karamouzian","year":"2018","unstructured":"Karamouzian M, Dohoo C, Forsting S, McNeil R, Kerr T, Lysyshyn M. Evaluation of a fentanyl drug checking service for clients of a supervised injection facility, Vancouver, Canada. Harm Reduct J. 2018;15(1):46.","journal-title":"Harm Reduct J"},{"key":"1242_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2020.108006","volume":"212","author":"L Ti","year":"2020","unstructured":"Ti L, Tobias S, Lysyshyn M, Laing R, Nosova E, Choi J, et al. Detecting fentanyl using point-of-care drug checking technologies: a validation study. Drug Alcohol Depend. 2020;212: 108006.","journal-title":"Drug Alcohol Depend"},{"key":"1242_CR46","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.drugpo.2018.10.001","volume":"62","author":"MK Laing","year":"2018","unstructured":"Laing MK, Tupper KW, Fairbairn N. Drug checking as a potential strategic overdose response in the fentanyl era. Int J Drug Policy. 2018;62:59\u201366.","journal-title":"Int J Drug Policy"},{"key":"1242_CR47","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.drugalcdep.2018.06.020","volume":"190","author":"KW Tupper","year":"2018","unstructured":"Tupper KW, McCrae K, Garber I, Lysyshyn M, Wood E. Initial results of a drug checking pilot program to detect fentanyl adulteration in a Canadian setting. Drug Alcohol Depend. 2018;190:242\u20135.","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"1242_CR48","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1186\/s12889-021-11243-4","volume":"21","author":"B Wallace","year":"2021","unstructured":"Wallace B, van Roode T, Pagan F, Hore D, Pauly B. The potential impacts of community drug checking within the overdose crisis: qualitative study exploring the perspective of prospective service users. BMC Public Health. 2021;21(1):1156.","journal-title":"BMC Public Health"},{"issue":"1","key":"1242_CR49","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s12954-020-00373-4","volume":"17","author":"B Wallace","year":"2020","unstructured":"Wallace B, van Roode T, Pagan F, Phillips P, Wagner H, Calder S, et al. What is needed for implementing drug checking services in the context of the overdose crisis? A qualitative study to explore perspectives of potential service users. Harm Reduct J. 2020;17(1):29.","journal-title":"Harm Reduct J"},{"key":"1242_CR50","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.drugalcdep.2018.10.017","volume":"194","author":"JL Glick","year":"2019","unstructured":"Glick JL, Christensen T, Park JN, McKenzie M, Green TC, Sherman SG. Stakeholder perspectives on implementing fentanyl drug checking: Results from a multi-site study. Drug Alcohol Depend. 2019;194:527\u201332.","journal-title":"Drug Alcohol Depend"},{"issue":"3","key":"1242_CR51","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1037\/pha0000486","volume":"29","author":"SB Dolan","year":"2021","unstructured":"Dolan SB, Johnson MW, Dunn KE, Huhn AS. The discounting of death: probability discounting of heroin use by fatal overdose likelihood and drug purity. Exp Clin Psychopharmacol. 2021;29(3):219\u201328.","journal-title":"Exp Clin Psychopharmacol"},{"key":"1242_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2023.103972","volume":"114","author":"R Magnolini","year":"2023","unstructured":"Magnolini R, Schneider M, Schori D, Trachsel D, Bruggmann P. Substances from unregulated drug markets - A retrospective data analysis of customer-provided samples from a decade of drug checking service in Zurich (Switzerland). Int J Drug Policy. 2023;114: 103972.","journal-title":"Int J Drug Policy"},{"issue":"3","key":"1242_CR53","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1111\/add.15734","volume":"117","author":"N Maghsoudi","year":"2022","unstructured":"Maghsoudi N, Tanguay J, Scarfone K, Rammohan I, Ziegler C, Werb D, et al. Drug checking services for people who use drugs: a systematic review. Addiction. 2022;117(3):532\u201344.","journal-title":"Addiction"},{"key":"1242_CR54","unstructured":"La Mantia, Alexandra; Oechslin, Lukas; Duarte, Marcelo; Laubereau, Birgit; Fabian, Carlo (2020): Studie zu den Effekten der Drug-Checking-Angebote in der Schweiz. Bericht zuhanden des Bundes- amts f\u00fcr Gesundheit (BAG), Interface Politikstudien Forschung Beratung und Fachhochschule Nordwestschweiz FHNW, Luzern\/Muttenz."},{"key":"1242_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2023.104139","volume":"119","author":"T Piatkowski","year":"2023","unstructured":"Piatkowski T, Puljevic C, Francis C, Ferris J, Dunn M. \u201cThey sent it away for testing and it was all bunk\u201d: exploring perspectives on drug checking among steroid consumers in Queensland. Australia Int J Drug Policy. 2023;119: 104139.","journal-title":"Australia Int J Drug Policy"},{"issue":"1","key":"1242_CR56","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s12954-020-00387-y","volume":"17","author":"E Frude","year":"2020","unstructured":"Frude E, McKay FH, Dunn M. A focused netnographic study exploring experiences associated with counterfeit and contaminated anabolic-androgenic steroids. Harm Reduct J. 2020;17(1):42.","journal-title":"Harm Reduct J"},{"key":"1242_CR57","doi-asserted-by":"publisher","unstructured":"Magnolini R, Senkoro E, Kalinjuma AV et al. Stigma-directed services (Stig2Health) to improve \u2018linkage to care\u2019 for people living with HIV in rural Tanzania: study protocol for a nested pre-post implementation study within the Kilombero and Ulanga Antiretroviral Cohort [version 2; peer review: 2 approved]. AAS Open Res 2022, 5:14 https:\/\/doi.org\/10.12688\/aasopenres.13353.2.","DOI":"10.12688\/aasopenres.13353.2"},{"issue":"10","key":"1242_CR58","doi-asserted-by":"publisher","first-page":"906","DOI":"10.2174\/1570159X18666200413142632","volume":"18","author":"A Guirguis","year":"2020","unstructured":"Guirguis A, Moosa I, Gittins R, Schifano F. What about drug checking? Systematic review and netnographic analysis of social media. Curr Neuropharmacol. 2020;18(10):906\u201317.","journal-title":"Curr Neuropharmacol"},{"key":"1242_CR59","doi-asserted-by":"publisher","DOI":"10.1111\/add.70009","author":"T Piatkowski","year":"2025","unstructured":"Piatkowski T, Coomber R, Francis C, Kill E, Davey G, Cresswell S, et al. The world\u2019s first anabolic-androgenic steroid testing trial: a two-phase pilot combining chemical analysis, results dissemination and community feedback. Addiction. 2025. https:\/\/doi.org\/10.1111\/add.70009.","journal-title":"Addiction"},{"key":"1242_CR60","unstructured":"WEDINOS . Annual Report. (20 14 ). https:\/\/www.wedinos.org\/resources\/downloads\/WN%20Annual%20Report%205012015.pdf."},{"key":"1242_CR61","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2288-10-1","volume":"10","author":"L Thabane","year":"2010","unstructured":"Thabane L, Ma J, Chu R, Cheng J, Ismaila A, Rios LP, et al. A tutorial on pilot studies: the what, why and how. BMC Med Res Methodol. 2010;10:1.","journal-title":"BMC Med Res Methodol"},{"issue":"5","key":"1242_CR62","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.1111\/hex.13577","volume":"25","author":"C Adams","year":"2022","unstructured":"Adams C, Walpola R, Schembri AM, Harrison R. The ultimate question? Evaluating the use of net promoter score in healthcare: a systematic review. Health Expect. 2022;25(5):2328\u201339.","journal-title":"Health Expect"},{"issue":"3","key":"1242_CR63","doi-asserted-by":"publisher","first-page":"413","DOI":"10.9745\/GHSP-D-18-00068","volume":"6","author":"R Koladycz","year":"2018","unstructured":"Koladycz R, Fernandez G, Gray K, Marriott H. The net promoter score (NPS) for insight into client experiences in sexual and reproductive health clinics. Glob Health Sci Pract. 2018;6(3):413\u201324.","journal-title":"Glob Health Sci Pract"},{"key":"1242_CR64","doi-asserted-by":"publisher","first-page":"237437352412936","DOI":"10.1177\/23743735241293631","volume":"11","author":"AJ \u00c4mm\u00e4l\u00e4","year":"2024","unstructured":"\u00c4mm\u00e4l\u00e4 AJ, Taimela S. Association between patient-reported enablement and customer satisfaction in 140 055 primary care patients after doctor appointment. J Patient Exp. 2024;11:23743735241293630.","journal-title":"J Patient Exp"},{"issue":"6","key":"1242_CR65","doi-asserted-by":"publisher","first-page":"601","DOI":"10.4097\/kjae.2017.70.6.601","volume":"70","author":"J In","year":"2017","unstructured":"In J. Introduction of a pilot study. Korean J Anesthesiol. 2017;70(6):601\u20135.","journal-title":"Korean J Anesthesiol"},{"issue":"1","key":"1242_CR66","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1186\/s12889-019-7288-x","volume":"19","author":"O Harvey","year":"2019","unstructured":"Harvey O, Keen S, Parrish M, van Teijlingen E. Support for people who use anabolic androgenic steroids: a systematic scoping review into what they want and what they access. BMC Public Health. 2019;19(1):1024.","journal-title":"BMC Public Health"},{"key":"1242_CR67","unstructured":"Barratt MJ, Kowalski M, Maier LJ, Ritter A. Global review of drug checking\u00a0services operating in 2017. Drug Policy Modelling Program Bulletin No. 24. Sydney, Australia:\u00a0National Drug and Alcohol Research Centre, UNSW Sydney. 2018"},{"issue":"8","key":"1242_CR68","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1592\/phco.31.8.757","volume":"31","author":"EJ Ip","year":"2011","unstructured":"Ip EJ, Barnett MJ, Tenerowicz MJ, Perry PJ. The Anabolic 500 survey: characteristics of male users versus nonusers of anabolic-androgenic steroids for strength training. Pharmacotherapy. 2011;31(8):757\u201366.","journal-title":"Pharmacotherapy"},{"issue":"2","key":"1242_CR69","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.yhbeh.2012.12.009","volume":"64","author":"RL Cunningham","year":"2013","unstructured":"Cunningham RL, Lumia AR, McGinnis MY. Androgenic anabolic steroid exposure during adolescence: ramifications for brain development and behavior. Horm Behav. 2013;64(2):350\u20136.","journal-title":"Horm Behav"},{"issue":"3","key":"1242_CR70","doi-asserted-by":"publisher","first-page":"105","DOI":"10.3810\/psm.2010.10.1815","volume":"38","author":"MK Mulcahey","year":"2010","unstructured":"Mulcahey MK, Schiller JR, Hulstyn MJ. Anabolic steroid use in adolescents: identification of those at risk and strategies for prevention. Phys Sportsmed. 2010;38(3):105\u201313.","journal-title":"Phys Sportsmed"},{"key":"1242_CR71","doi-asserted-by":"publisher","DOI":"10.1080\/09687637.2022.2132135","author":"E Hearne","year":"2022","unstructured":"Hearne E, Atkinson A, Boardley I, McVeigh J, Hout MCV. \u2018Sustaining masculinity\u2019: a scoping review of anabolic androgenic steroid use by older males. Drugs Edu Prevent Policy. 2022. https:\/\/doi.org\/10.1080\/09687637.2022.2132135.","journal-title":"Drugs Edu Prevent Policy"},{"issue":"5","key":"1242_CR72","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1177\/0897190014527319","volume":"28","author":"EJ Ip","year":"2015","unstructured":"Ip EJ, Trinh K, Tenerowicz MJ, Pal J, Lindfelt TA, Perry PJ. Characteristics and behaviors of older male anabolic steroid users. J Pharm Pract. 2015;28(5):450\u20136.","journal-title":"J Pharm Pract"},{"issue":"5","key":"1242_CR73","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1007\/s40279-022-01801-0","volume":"53","author":"JM Smoliga","year":"2023","unstructured":"Smoliga JM, Wilber ZT, Robinson BT. Premature death in bodybuilders: What do we know? Sports Med. 2023;53(5):933\u201348.","journal-title":"Sports Med"},{"issue":"12","key":"1242_CR74","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.1111\/add.16643","volume":"119","author":"T Piatkowski","year":"2024","unstructured":"Piatkowski T, Whiteside B, Robertson J, Henning A, Lau EHY, Dunn M. What is the prevalence of anabolic-androgenic steroid use among women? A systematic review. Addiction. 2024;119(12):2088\u2013100.","journal-title":"Addiction"},{"key":"1242_CR75","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2020.102876","volume":"95","author":"IA Havnes","year":"2021","unstructured":"Havnes IA, J\u00f8rstad ML, Innerdal I, Bj\u00f8rnebekk A. Anabolic-androgenic steroid use among women - a qualitative study on experiences of masculinizing, gonadal and sexual effects. Int J Drug Policy. 2021;95: 102876.","journal-title":"Int J Drug Policy"},{"issue":"2","key":"1242_CR76","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1159\/000333037","volume":"18","author":"A Hakansson","year":"2012","unstructured":"Hakansson A, Mickelsson K, Wallin C, Berglund M. Anabolic androgenic steroids in the general population: user characteristics and associations with substance use. Eur Addict Res. 2012;18(2):83\u201390.","journal-title":"Eur Addict Res"},{"issue":"13","key":"1242_CR77","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1080\/10826080601006367","volume":"41","author":"S Pallesen","year":"2006","unstructured":"Pallesen S, J\u00f8sendal O, Johnsen BH, Larsen S, Molde H. Anabolic steroid use in high school students. Subst Use Misuse. 2006;41(13):1705\u201317.","journal-title":"Subst Use Misuse"},{"issue":"1\u20133","key":"1242_CR78","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.drugalcdep.2009.02.008","volume":"102","author":"G Kanayama","year":"2009","unstructured":"Kanayama G, Hudson JI, Pope HG. Features of men with anabolic-androgenic steroid dependence: a comparison with nondependent AAS users and with AAS nonusers. Drug Alcohol Depend. 2009;102(1\u20133):130\u20137.","journal-title":"Drug Alcohol Depend"},{"issue":"20","key":"1242_CR79","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/NEJM200005183422018","volume":"342","author":"D Arvary","year":"2000","unstructured":"Arvary D, Pope HG. Anabolic-androgenic steroids as a gateway to opioid dependence. N Engl J Med. 2000;342(20):1532.","journal-title":"N Engl J Med"},{"issue":"2","key":"1242_CR80","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.jsps.2018.11.007","volume":"27","author":"FF Alharbi","year":"2019","unstructured":"Alharbi FF, Gamaleddin I, Alharbi SF, Almodayfer O, Allohidan F, Alghobain M, et al. Knowledge, attitudes and use of anabolic-androgenic steroids among male gym users: a community based survey in Riyadh. Saudi Arabia Saudi Pharm J. 2019;27(2):254\u201363.","journal-title":"Saudi Arabia Saudi Pharm J"},{"issue":"1","key":"1242_CR81","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1081\/JA-200030485","volume":"40","author":"S Nilsson","year":"2005","unstructured":"Nilsson S, Spak F, Marklund B, Baigi A, Allebeck P. Attitudes and behaviors with regards to androgenic anabolic steroids among male adolescents in a county of Sweden. Subst Use Misuse. 2005;40(1):1\u201312.","journal-title":"Subst Use Misuse"},{"issue":"3","key":"1242_CR82","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1080\/09540121.2015.1090539","volume":"28","author":"EJ Ip","year":"2016","unstructured":"Ip EJ, Yadao MA, Shah BM, Lau B. Infectious disease, injection practices, and risky sexual behavior among anabolic steroid users. AIDS Care. 2016;28(3):294\u20139.","journal-title":"AIDS Care"},{"issue":"1","key":"1242_CR83","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1001\/jama.2016.17441","volume":"317","author":"HG Pope","year":"2017","unstructured":"Pope HG, Khalsa JH, Bhasin S. Body image disorders and abuse of anabolic-androgenic steroids among men. JAMA. 2017;317(1):23\u20134.","journal-title":"JAMA"},{"issue":"6","key":"1242_CR84","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1080\/10826084.2016.1263665","volume":"52","author":"C Weber","year":"2017","unstructured":"Weber C, Krug O, Kamber M, Thevis M. Qualitative and semiquantitative analysis of doping products seized at the swiss border. Subst Use Misuse. 2017;52(6):742\u201353.","journal-title":"Subst Use Misuse"},{"issue":"11","key":"1242_CR85","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1007\/s00228-014-1743-5","volume":"70","author":"O Krug","year":"2014","unstructured":"Krug O, Thomas A, Walpurgis K, Piper T, Sigmund G, Sch\u00e4nzer W, et al. Identification of black market products and potential doping agents in Germany 2010\u20132013. Eur J Clin Pharmacol. 2014;70(11):1303\u201311.","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"1242_CR86","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1080\/15563650.2020.1770277","volume":"59","author":"S Odoardi","year":"2021","unstructured":"Odoardi S, Mestria S, Biosa G, Valentini V, Federici S, Strano RS. An overview on performance and image enhancing drugs (PIEDs) confiscated in Italy in the period 2017\u20132019. Clin Toxicol (Phila). 2021;59(1):47\u201352.","journal-title":"Clin Toxicol (Phila)"},{"key":"1242_CR87","doi-asserted-by":"publisher","DOI":"10.1017\/CBO9781139003353","volume-title":"Testosterone: Action, Deficiency","author":"E Nieschlag","year":"2012","unstructured":"Nieschlag E. Testosterone: Action, Deficiency. Substitution: Cambridge University Press; 2012."},{"issue":"3","key":"1242_CR88","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1038\/bjp.2008.165","volume":"154","author":"AT Kicman","year":"2008","unstructured":"Kicman AT. Pharmacology of anabolic steroids. Br J Pharmacol. 2008;154(3):502\u201321.","journal-title":"Br J Pharmacol"},{"issue":"6","key":"1242_CR89","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1111\/dar.13656","volume":"42","author":"TM Piatkowski","year":"2023","unstructured":"Piatkowski TM, Neumann DL, Dunn M. \u201cMy mind pretty much went to mush\u201d: a qualitative exploration of trenbolone in the performance and image enhancing drug community. Drug Alcohol Rev. 2023;42(6):1566\u201376.","journal-title":"Drug Alcohol Rev"},{"issue":"3","key":"1242_CR90","doi-asserted-by":"publisher","first-page":"267","DOI":"10.5603\/ep.99130","volume":"75","author":"R Borecki","year":"2024","unstructured":"Borecki R, Byczkiewicz P, S\u0142owikowska-Hilczer J. Impact of trenbolone on selected organs. Endokrynol Pol. 2024;75(3):267\u201378.","journal-title":"Endokrynol Pol"},{"key":"1242_CR91","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1477-7517-8-16","volume":"8","author":"I Hungerbuehler","year":"2011","unstructured":"Hungerbuehler I, Buecheli A, Schaub M. Drug Checking: a prevention measure for a heterogeneous group with high consumption frequency and polydrug use - evaluation of zurich\u2019s drug checking services. Harm Reduct J. 2011;8:16.","journal-title":"Harm Reduct J"},{"key":"1242_CR92","volume-title":"Pill testing, ecstasy and prevention: a scientific evaluation in three European cities","author":"D Korf","year":"2002","unstructured":"Korf D, Benschop A, Rabes M. Pill testing, ecstasy and prevention: a scientific evaluation in three European cities. Amsterdam: Rozenberg; 2002."},{"issue":"9","key":"1242_CR93","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1007\/s40279-017-0709-z","volume":"47","author":"MA Christou","year":"2017","unstructured":"Christou MA, Christou PA, Markozannes G, Tsatsoulis A, Mastorakos G, Tigas S. Effects of anabolic androgenic steroids on the reproductive system of athletes and recreational users: a systematic review and meta-analysis. Sports Med. 2017;47(9):1869\u201383.","journal-title":"Sports Med"},{"issue":"7","key":"1242_CR94","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-056445","volume":"12","author":"JMX Amaral","year":"2022","unstructured":"Amaral JMX, Kimerg\u00e5rd A, Deluca P. Prevalence of anabolic steroid users seeking support from physicians: a systematic review and meta-analysis. BMJ Open. 2022;12(7): e056445.","journal-title":"BMJ Open"},{"key":"1242_CR95","doi-asserted-by":"publisher","first-page":"4225","DOI":"10.57187\/s.4225","volume":"155","author":"R Magnolini","year":"2025","unstructured":"Magnolini R, Kossinna K, Bjasch D, Kruijver M, Bruggmann P, Senn O. Feasibility of implementing current best clinical practice for people who are using anabolic androgenic steroids within a Swiss primary care practice: a quality assurance study. Swiss Med Wkly. 2025;155:4225.","journal-title":"Swiss Med Wkly"},{"issue":"5","key":"1242_CR96","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1080\/09595230801956132","volume":"27","author":"CA Day","year":"2008","unstructured":"Day CA, Topp L, Iversen J, Maher L. NSPs CoA Blood-borne virus prevalence and risk among steroid injectors: results from the Australian needle and syringe program survey. Drug Alcohol Rev. 2008;27(5):559\u201361.","journal-title":"Drug Alcohol Rev"},{"issue":"1","key":"1242_CR97","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1111\/dar.12085","volume":"33","author":"M Dunn","year":"2014","unstructured":"Dunn M, McKay FH, Iversen J. Steroid users and the unique challenge they pose to needle and syringe program workers. Drug Alcohol Rev. 2014;33(1):71\u20137.","journal-title":"Drug Alcohol Rev"},{"issue":"1","key":"1242_CR98","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s12954-023-00761-6","volume":"20","author":"R Brien","year":"2023","unstructured":"Brien R, Volpe I, Grigg J, Lyons T, Hughes C, McKinnon G, et al. Co-designing drug alerts for health and community workers for an emerging early warning system in Victoria, Australia. Harm Reduct J. 2023;20(1):30.","journal-title":"Harm Reduct J"},{"key":"1242_CR99","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.jpba.2013.05.024","volume":"83","author":"D Favretto","year":"2013","unstructured":"Favretto D, Castagna F, Maietti S, Boscolo-Berto R, Ferrara SD. When color fails: illicit blue tablets containing anabolic androgen steroids. J Pharm Biomed Anal. 2013;83:260\u20134.","journal-title":"J Pharm Biomed Anal"},{"key":"1242_CR100","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.forsciint.2018.12.022","volume":"296","author":"LM Berneira","year":"2019","unstructured":"Berneira LM, de Freitas SC, da Silva CC, Machado AM, de Pereira CMP, Dos Santos MAZ. Application of differential scanning calorimetry in the analysis of apprehended formulations of anabolic androgenic steroids. Forensic Sci Int. 2019;296:15\u201321.","journal-title":"Forensic Sci Int"},{"issue":"3","key":"1242_CR101","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1093\/jat\/32.3.232","volume":"32","author":"M Thevis","year":"2008","unstructured":"Thevis M, Schrader Y, Thomas A, Sigmund G, Geyer H, Sch\u00e4nzer W. Analysis of confiscated black market drugs using chromatographic and mass spectrometric approaches. J Anal Toxicol. 2008;32(3):232\u201340.","journal-title":"J Anal Toxicol"},{"key":"1242_CR102","doi-asserted-by":"publisher","DOI":"10.1016\/j.forsciint.2021.110771","volume":"322","author":"N Fabresse","year":"2021","unstructured":"Fabresse N, Gheddar L, Kintz P, Knapp A, Larabi IA, Alvarez JC. Analysis of pharmaceutical products and dietary supplements seized from the black market among bodybuilders. Forensic Sci Int. 2021;322: 110771.","journal-title":"Forensic Sci Int"},{"issue":"11\u201312","key":"1242_CR103","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1002\/dta.1900","volume":"7","author":"IR Hullstein","year":"2015","unstructured":"Hullstein IR, Malerod-Fjeld H, Dehnes Y, Hemmersbach P. Black market products confiscated in Norway 2011\u20132014 compared to analytical findings in urine samples. Drug Test Anal. 2015;7(11\u201312):1025\u20139.","journal-title":"Drug Test Anal"},{"key":"1242_CR104","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.ijms.2015.08.022","volume":"392","author":"EA Prokudina","year":"2015","unstructured":"Prokudina EA, Prchalov\u00e1 J, Vy\u0161atov\u00e1 E, Kucha\u0159 M, Rajchl A, Lap\u010d\u00edk O. Analysis of anabolic androgenic steroids by direct analysis in real time ionization with time-of-flight mass spectrometry. Int J Mass Spectrom. 2015;392:28\u201333. https:\/\/doi.org\/10.1016\/j.ijms.2015.08.022.","journal-title":"Int J Mass Spectrom"},{"issue":"5\u20136","key":"1242_CR105","first-page":"152","volume":"199","author":"F Musshoff","year":"1997","unstructured":"Musshoff F, Daldrup T, Ritsch M. Anabolic steroids on the German black market. Arch Kriminol. 1997;199(5\u20136):152\u20138.","journal-title":"Arch Kriminol"},{"issue":"2","key":"1242_CR106","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1123\/ijsnem.11.2.258","volume":"11","author":"M Kamber","year":"2001","unstructured":"Kamber M, Baume N, Saugy M, Rivier L. Nutritional supplements as a source for positive doping cases? Int J Sport Nutr Exerc Metab. 2001;11(2):258\u201363.","journal-title":"Int J Sport Nutr Exerc Metab"}],"container-title":["Harm Reduction Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-025-01242-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12954-025-01242-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-025-01242-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,8]],"date-time":"2025-06-08T19:02:13Z","timestamp":1749409333000},"score":1,"resource":{"primary":{"URL":"https:\/\/harmreductionjournal.biomedcentral.com\/articles\/10.1186\/s12954-025-01242-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,8]]},"references-count":106,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1242"],"URL":"https:\/\/doi.org\/10.1186\/s12954-025-01242-8","relation":{},"ISSN":["1477-7517"],"issn-type":[{"value":"1477-7517","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,8]]},"assertion":[{"value":"22 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The present pilot study was reviewed by the Cantonal Ethics Committee Zurich, Switzerland (BASEC-Nr.: Req- 2024\u201300240) and did not fall within the scope of the Human Research Act (HRA). During the consultation, clients were explained the nature of data collection\u00a0and that filling out a questionnaire would be consent for it to be used for research purposes. Clients could decide whether to complete a questionnaire. Clients who wished to reject the questionnaire received the same standard procedure as clients who accepted it.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Verbal informed consent was obtained from participants prior to the conduct of the questionnaire and they were explained the voluntary nature of the anonymous questionnaire.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"100"}}